drugset / Trial / NCT04973020
A Drug-drug Interaction Study of SHR6390 on Healthy Chinese Volunteers
NaSingle-groupOpen-labelBasic science
Summary
The study is a single-center, open, single-dose, self-controlled clinical trial. It is planned to enroll 20 healthy adult subjects.Subjects will take the SHR6390 on Day1 and Day22 , and from Day8 to Day26 take the efavirenz.
Timeline
- Start
- 2021-09-01
- Primary completion
- 2021-10-28
- Completion
- 2021-10-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dalpiciclib | Small molecule | 150 mg | Oral |
| Subject | Efavirenz | Other / unclassified | 600 mg | Oral |